10/542313

JC17FREEFOFETPPETSATISMUL 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: R. Guiles

Appln. No.: PCT/US04/002543

Group Art Unit: To be assigned

Filed: January 30, 2004

Examiner: To be assigned

For: NOVEL COMPOUNDS FOR THE TREATMENT OF SICKLE CELL DISEASE

## INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

A copy of each reference on the PTO/SB/08 is provided herein.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.57(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be

Attorney Docket No. RG-2002-002 Application No. PCT/US04/002543 10.1542313<sub>Page 2</sub>

JC17 Rec'd FCT/FTO 15 JUL 2005

an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 21-0684. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 50,931

University of Maryland, Baltimore

Telephone: (410) 706-2378 Facsimile: (410) 706-1066

Date: July 15, 2005.

Express mail: EV 600208537 US

## JC17 Rec'd FOT/PTO 15 JUL 2005

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known			
		Application Number	PCT/US04/002543	13	
	INFORMATION DISCLOSURE	Filing Date			
		First Named Inventor	Ronald D. Guiles		
	STATEMENT BY APPLICANT	Art Unit			
	(Use as many sheets as necessary)	Examiner Name			
SI	neet of	Attorney Docket Number	RG-2002-002		

			U. S. PATENT		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan
		Number-Kind Code <sup>2 (# known)</sup>			Figures Appear
		US-			ĺ
•		US-			
		US-			
-		US-			
		US-			-
		US-			
		US- °			
		US-			
		ŲS-			
		US-			
		US-			
		US-	1		
		US-			·
		US-		· · · · · · · · · · · · · · · · · · ·	
		US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T		
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	, ,	Or Relevant Figures Appear			
						┡		
<u> </u>						╄		
						┢		
<del></del>				<u> </u>	-	┡		

Examiner	Date	
Signature	Considered	
-		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

## JC17 Rec'd PCT/PTO 15 JUL 2005

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

		uction A	t of 1995, no persons ar	are required to respond to a collection of information unless it contains a fail DMD control number.  Complete if Known		
Substitute for form 1449/PTO				Application Number	PCT/US04/002543	13
INF	ORMATION	DIS	CLOSURE	Filing Date		
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Ronald D. Guiles	
	(Use as many she	ata aa n	00000000	Art Unit		
	(Use as many sne	eis as n	ecessary)	Examiner Name		
Sheet		of		Attorney Docket Number	RG-2002-002	

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		HOSSEINI M W. ET AL., "Multiple molecular recognition and catalysis. A multifunctional anion receptor bearing an anion binding site, an intercalating group and a catalytic	
		site for nucleotide binding and hydrolysis," Journal of the American Chemical Society, 1990, 3896-3904.	
		LOMOZIK, LECHOSLAW ET AL., "Copper(II) ions as a factor interfering in the interaction between bioligands in systems with adenosine and polyamines," Journal of Inorganic	
		Biochemistry, 1996, 63(3), 191-206.	
		FENNIRI, HITCHAM ET AL., "Molecular recognistion of NADP(H) and ATP by macrocyclic polyamines bearing acridine groups," Helvetica Chimica Acta, 1997, 80(3), 786-803.	
		POL'SHAKOV, V I ET AL., "Interaction of the antitumor drugs prospidin and spiroboromin with nucleotides," Khimiko-Farmatsevticheskii Zhurnal, 1987, 21(5), 528-36.	
		POL'SHAKOV, VI ET AL., "Interaction of spirazidine, prospidine, and spirobromine with nucleic acid components," Khimiko-Farmatsevticheskii Zhurnal, 1989, 23(1), 10-16.	
_			

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.